Burning Rock Biotech (BNR) Current Deferred Revenue (2020 - 2024)
Historic Current Deferred Revenue for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $15.0 million.
- Burning Rock Biotech's Current Deferred Revenue fell 524.68% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 524.68%. This contributed to the annual value of $16.2 million for FY2024, which is 1215.05% down from last year.
- As of Q3 2025, Burning Rock Biotech's Current Deferred Revenue stood at $15.0 million, which was down 524.68% from $14.4 million recorded in Q2 2025.
- In the past 5 years, Burning Rock Biotech's Current Deferred Revenue ranged from a high of $133.5 million in Q4 2021 and a low of $3.0 million during Q2 2022
- In the last 5 years, Burning Rock Biotech's Current Deferred Revenue had a median value of $17.7 million in 2024 and averaged $23.6 million.
- Per our database at Business Quant, Burning Rock Biotech's Current Deferred Revenue skyrocketed by 107064.81% in 2021 and then crashed by 8396.5% in 2022.
- Burning Rock Biotech's Current Deferred Revenue (Quarter) stood at $133.5 million in 2021, then crashed by 83.96% to $21.4 million in 2022, then fell by 14.1% to $18.4 million in 2023, then decreased by 12.15% to $16.2 million in 2024, then decreased by 7.42% to $15.0 million in 2025.
- Its Current Deferred Revenue was $15.0 million in Q3 2025, compared to $14.4 million in Q2 2025 and $16.2 million in Q1 2025.